Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Renalytix ( (GB:RENX) ) has shared an announcement.
Renalytix has expanded the clinical footprint of its kidneyintelX.dkd test in the US by completing three new electronic health record-integrated deployments with regional kidney care providers in New York, Florida and Tennessee, with testing now underway and a focus on one-click ordering to encourage gradual growth in utilisation. The company is pursuing a measured, resource-efficient rollout strategy and deepening its collaboration with Tempus AI to integrate kidneyintelX.dkd within major health systems’ electronic records and data infrastructures, supporting future geographic and clinical expansion, while simultaneously stepping up investor engagement at the J.P. Morgan Healthcare Conference ahead of a wider trading and corporate update expected in February 2026.
The most recent analyst rating on (GB:RENX) stock is a Hold with a £5.50 price target. To see the full list of analyst forecasts on Renalytix stock, see the GB:RENX Stock Forecast page.
Spark’s Take on GB:RENX Stock
According to Spark, TipRanks’ AI Analyst, GB:RENX is a Neutral.
The score is held down primarily by weak financial performance (large losses, negative equity, and ongoing cash burn) and a bearish technical trend (price below key moving averages and negative MACD). Positive corporate updates and oversold signals provide some support, but they do not offset current financial and trend risk.
To see Spark’s full report on GB:RENX stock, click here.
More about Renalytix
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on improving clinical management of chronic kidney disease through its flagship prognostic test, kidneyintelX.dkd, the only FDA-approved and Medicare-reimbursed assay for early-stage risk assessment in diabetic kidney disease. The company targets large physician group practices and health systems in the United States, where kidneyintelX.dkd is commercially available and supported by real-world performance data, inclusion in international CKD guidelines, and full Medicare reimbursement at $950 per reportable result.
YTD Price Performance: 5.93%
Average Trading Volume: 1,111,953
Technical Sentiment Signal: Sell
Current Market Cap: £27.31M
See more insights into RENX stock on TipRanks’ Stock Analysis page.